NOVARTIS STUDY

Safe and beneficial treatment options are urgently needed to improve quality of life for patients and families facing Alzheimer's. The purpose of this study is to assess the safety and potential beneficial effects of the investigational medication VHB937 in treating symptoms of Alzheimer's disease (AD).

Who Can Participate?

- Adults aged 50 – 85 with Mild Cognitive Impairment (MCI) or dementia due to AD.

Study Details

- The screening period lasts approximately two months, followed by an 18- month intervention period, and a five-month follow-up period. Total participation could last approximately 25 months.
- Memory and thinking tests, questionnaires, blood draws, urine tests, physical and neurological exam, ECG, and MRI. PET scan or lumbar puncture may also be needed.

Learn More

Please call **(913) 588-0555** or
Visit **kuadrc.org/novartis**

KU
ALZHEIMER'S DISEASE RESEARCH CENTER
The University of Kansas Medical Center